WallStreetZenWallStreetZen

NASDAQ: AGLE
Aeglea Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for AGLE

Based on 3 analysts offering 12 month price targets for Aeglea Biotherapeutics Inc.
Min Forecast
$1.00+233.33%
Avg Forecast
$2.33+677.67%
Max Forecast
$4.00+1,233.33%

Should I buy or sell AGLE stock?

Based on 4 analysts offering ratings for Aeglea Biotherapeutics Inc.
Buy
Strong Buy
2 analysts 50%
Buy
0 analysts 0%
Hold
2 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AGLE stock forecasts and price targets.

AGLE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Bottom 19%
19
HoldMaintains$1.00+233.33%2023-03-03
Wells Fargo
Bottom 2%
2
Strong BuyUpgrades$2.00+566.67%2022-10-28
Needham
Bottom 3%
3
HoldDowngradesN/AN/A2022-06-03
Piper Sandler
Bottom 8%
8
Strong BuyMaintains$4.00+1,233.33%2022-05-23

1 of 1

Forecast return on equity

Is AGLE forecast to generate an efficient return?
Company
-61.1%
Industry
0.12%
Market
51.59%
AGLE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AGLE forecast to generate an efficient return on assets?
Company
-43.2%
Industry
3.48%
AGLE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AGLE earnings per share forecast

What is AGLE's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
-$0.82
Avg 2 year Forecast
-$0.47

AGLE revenue forecast

What is AGLE's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$1.8M-24.3%
Avg 2 year Forecast
$47.6M+1,944.74%
AGLE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AGLE revenue growth forecast

How is AGLE forecast to perform vs Biotechnology companies and vs the US market?
Company
-24.3%
Industry
248.95%
Market
25.87%
AGLE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AGLE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AGLE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AGLE$0.30$2.33+677.67%Buy
CYAD$0.86$11.00+1,176.10%Strong Buy
ACST$0.43$2.45+464.52%Strong Buy
FNCH$0.40$17.00+4,150.00%Strong Buy
MTEM$0.34$1.25+270.92%Buy
View Top Biotech Stocks

Aeglea Biotherapeutics Stock Forecast FAQ

Is Aeglea Biotherapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: AGLE) stock is to Buy AGLE stock.

Out of 4 analysts, 2 (50%) are recommending AGLE as a Strong Buy, 0 (0%) are recommending AGLE as a Buy, 2 (50%) are recommending AGLE as a Hold, 0 (0%) are recommending AGLE as a Sell, and 0 (0%) are recommending AGLE as a Strong Sell.

If you're new to stock investing, here's how to buy Aeglea Biotherapeutics stock.

What is AGLE's earnings growth forecast for 2023-2024?

(NASDAQ: AGLE) Aeglea Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 75.7%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 77.88%.

Aeglea Biotherapeutics's earnings in 2023 is -$83,815,000.On average, 2 Wall Street analysts forecast AGLE's earnings for 2023 to be -$53,624,030, with the lowest AGLE earnings forecast at -$66,703,062, and the highest AGLE earnings forecast at -$41,198,950.

In 2024, AGLE is forecast to generate -$30,735,725 in earnings, with the lowest earnings forecast at -$30,735,725 and the highest earnings forecast at -$30,735,725.

What is AGLE's revenue growth forecast for 2023-2024?

(NASDAQ: AGLE) Aeglea Biotherapeutics's forecast annual revenue growth rate of -24.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 248.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.87%.

Aeglea Biotherapeutics's revenue in 2023 is $2,329,000.On average, 1 Wall Street analysts forecast AGLE's revenue for 2023 to be $115,291,665, with the lowest AGLE revenue forecast at $115,291,665, and the highest AGLE revenue forecast at $115,291,665.

In 2024, AGLE is forecast to generate $3,114,248,262 in revenue, with the lowest revenue forecast at $3,114,248,262 and the highest revenue forecast at $3,114,248,262.

What is AGLE's forecast return on assets (ROA) for 2023-2024?

(NASDAQ: AGLE) forecast ROA is -43.2%, which is lower than the forecast US Biotechnology industry average of 3.48%.

What is AGLE's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AGLE price target, the average AGLE price target is $2.33, with the highest AGLE stock price forecast at $4.00 and the lowest AGLE stock price forecast at $1.00.

On average, Wall Street analysts predict that Aeglea Biotherapeutics's share price could reach $2.33 by Mar 3, 2024. The average Aeglea Biotherapeutics stock price prediction forecasts a potential upside of 677.67% from the current AGLE share price of $0.30.

What is AGLE's Earnings Per Share (EPS) forecast for 2023-2024?

(NASDAQ: AGLE) Aeglea Biotherapeutics's current Earnings Per Share (EPS) is -$0.99. On average, analysts forecast that AGLE's EPS will be -$0.82 for 2023, with the lowest EPS forecast at -$1.02, and the highest EPS forecast at -$0.63. In 2024, AGLE's EPS is forecast to hit -$0.47 (min: -$0.47, max: -$0.47).

What is AGLE's forecast return on equity (ROE) for 2023-2024?

(NASDAQ: AGLE) forecast ROE is -61.1%, which is considered weak.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.